The Standard in AML Today

For first-line combination therapy in adult AML Significantly fewer patients with resistant disease Significantly higher complete remission rates* Significantly longer survival* Superior therapeutic profile during induction* And options for postinduction therapy *In two of three US studies.

References

1. Skarin AT. Acute and chronic leukemias. In: Skarin AT, ed. Diagnostic Oncology. Gower Medical Publishing; 1991:chap 11. Reprinted by Wolfe Publishing; 1993.
2. Bennett JM, Catovsky D, Daniel M-T, et al. Proposal for the recognition of minimally differentiated acute myeloid leukemia (AML-MO). Br J Haematol. 1991;78:325-329.
3. Greer JP, Kinney MC. Acute nonlymphocytic leukemia. In: Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN, eds. Wintrobe's Clinical Hematology. Vol 2. 9th ed. Philadelphia, Pa: Lea & Febiger; 1993:1928.
4. Sandberg AA. The Chromosomes in Human Cancer and Leukemia. 2nd ed. New York, NY: Elsevier; 1990:223-312.
5. Keating MJ, Estey E, Kantarjian H. Acute leukemia. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 4th ed. Philadelphia, Pa: JB Lippincott Co; 1993:1938-1964.
6. Leukemia Society of America, Update. Facts about leukemia and related diseases:1993.
7. Sandberg AA. Cancer cytogenetics for clinicians. CA Cancer J Clin. May/June 1994;44:137-159.
8. Supino R, Necco A, Dasdia T, Casazza AM, Di Marco A. Relationship between effects on nucleic acid synthesis in cell cultures and cytotoxicity of 4-demethoxy derivatives of daunorubicin and Adriamycin. Cancer Res. 1977;37:4523-4528.
9. Zunino F, Gambetta R, Di Marco A, Luoni G, Zaccaro A. Effects of the stereochemical configuration on the interaction of some daunorubicin derivatives with DNA. Biochem Biophys Res Commun. 1976;69:744-756.
10. Schwartz HS, Kanter PM. DNA damage by anthracycline drugs in human leukemia cells. Cancer Lett. 1981;13:309-313.
11. Berman E. A review of idarubicin in acute leukemia. Oncology. October 1993;7:91-107.
12. Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study. J Clin Oncol. 1992;10:1103-1111.
13. Wiernik PH, Banks PLC, Case DC, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992;79:313-319.
14. Geller RB. Post-remission therapy of acute myelocytic leukemia in adults: curability breeds controversy. Leukemia. 1992;6:915-925.

Please see full prescribing information.

Top - Leukemia Library Index - AML Atlas Index